Notably, the 2024 FDA approval of Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and obesity/overweight (based on the SELECT trial) provides additional evidence of cardiometabolic benefits beyond glycemic control
Common injection site reactions It's possible to have a mild reaction right where you injected it
[1] GLP-1 receptor agonists (e.g., semaglutide/Wegovy, liraglutide/Saxenda): These injectable medications mimic the glucagon-like peptide-1 hormone, suppressing appetite and slowing gastric emptying
The page for each substance includes details such as side effects, answers to common questions and more, including instructions on how to get a prescription from your doctor
Seven of the patients developed NAION, one developed a stroke in the retina and the final patient developed swelling in both optic nerves
The practice took off in the summer of 2024